Platform enables the tailormade development of well-characterised polymeric nanoparticles of a specific size
Cristal Therapeutics, a privately-held life sciences company developing nanomedicines against cancer and other diseases, has entered into a joint research and development programme with PX Biosolutions of Melbourne, Australia to develop new vaccines.
Under the agreement, the companies will focus on the application of Cristal Therapeutics’ vaccine technology CriVac for the design of new vaccines.
The Maastricht, Netherlands-based company's CriVac platform enables the tailormade development of well-characterised polymeric nanoparticles of a specific size, which allow optimal antigen presentation to dendritic cells.
PX Biosolutions has developed DCtag vaccine formulations against various types of cancer, which have been tested successfully in animal models.
Cristal Therapeutics' Chief Executive Joost Holthuis said the collaboration fits the company's strategy to set up product developments with companies active in the vaccine area. 'We are convinced that we can create additional value for patients and vaccine companies by development of superior vaccine products based on our CriVac technology,' he said.